Abstract: The present invention relates generally to peptides and more specifically to anti-biofilm and immunomodulatory peptides.

Abstract: The present invention provides a method for treating a mammalian subject affected by prostate cancer comprising i) an oligonucleotide which reduces clusterin expression and ii) a Heat Shock Protein 90 (Hsp90) inhibitor each in an amount that when in combination with the other is effective to treat the mammalian subject. The present invention also provides pharmaceutical compositions comprising an amount of an oligonucleotide which reduces clusterin expression, and a Hsp90 inhibitor for use in treating a mammalian subject affected by prostate cancer. Also provided are oligonucleotides which reduce clusterin expression for use in combination with a Hsp90 inhibitor in treating a mammalian subject affected by prostate cancer, and a composition for treating a mammalian subject affected by prostate cancer comprising i) an oligonucleotide which reduces clusterin expression and ii) a Hsp90 inhibitor each in an amount that when in combination with the other is effective to treat the mammalian subject.

Abstract: Isolated polypeptides are disclosed herein, the isolated polypeptides comprising at least 90% identity to any one of: SEQ ID NO:1; SEQ ID NO:2; or SEQ ID NO:3, wherein the isolated polypeptide inhibits an interaction between palmitoyl acyl transferase zinc-finger DHHC type containing 17 (z D17) and c-jun N-terminal kinase (JNK). The polypeptides may be conjugated to a delivery and targeting moiety, such as the cell-membrane transduction domain of the HIV-1 Tat protein. There are also provided methods for treating a disease associated with cytotoxicity or excitotoxicity.

Abstract: Methods and apparatus for separating, concentrating and/or detecting molecules based on differences in binding affinity to a probe are provided. The molecules may be differentially modified. The molecules may be differentially methylated nucleic acids. The methods can be used in fields such as epigenetics or oncology to selectively concentrate or detect the presence of specific biomolecules or differentially modified biomolecules, to provide diagnostics for disorders such as fetal genetic disorders, to detect biomarkers in cancer, organ failure, disease states, infection or the like.

Abstract: A transducer is used to send an ultrasound pulse toward a stone and to receive ultrasound reflections from the stone. The recorded time between a pulse that is reflected from the proximal surface and a pulse that is reflected either from the distal surface of the stone or from a surface supporting the stone is used to calculate the stone size. The size of the stone is a function of the time between the two pulses and the speed of sound through the stone (or through the surrounding fluid if the second pulse was reflected by the surface supporting the stone). This technique is equally applicable to measure the size of other in vivo objects, including soft tissue masses, cysts, uterine fibroids, tumors, and polyps.

Abstract: Methods for characterizing two-dimensional concept drawings are disclosed. The concept drawings comprise cross-sections intersecting at cross-hairs. The method comprises: determining, for each cross-section: a plane on which the cross-section is located, the plane having a normal vector in a three-dimensional coordinate system; and, for each cross-hair on the cross-section, a tangent vector in the three-dimensional coordinate system which is tangent to the cross-section at the cross-hair. For each cross-hair comprising ith and jth intersecting cross-sections, one or more constraints are satisfied, the constraints comprising: the normal vector ni of the plane on which the ith cross-section is located is at least approximately orthogonal to the normal vector nj of the plane on which the jth cross-section is located; and the tangent vector tij to the ith cross-section at the cross-hair is at least approximately orthogonal to the tangent vector tji to the jth cross-section at the cross-hair.

Abstract: Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

Abstract: Limit size lipid nanoparticles, methods for using the lipid nanoparticles, and methods and systems for making limit size lipid nanoparticles.

Abstract: This invention provides bisphenol derivatives having a structure of formula 1. Said compounds are modulators of the androgen receptor activity and are useful in the treatment of various diseases, including prostate cancer, breast cancer, ovarian cancer, endometrial cancer, acne, ovarian cysts, polycystic ovarian disease, age-related macular degeneration, precocious puberty, hirsutism and hair loss.

Abstract: Compounds having a structure of Formula I and compositions comprising these compounds are provided. Uses of such compounds and compositions are provided for treatment or prophylaxis of viral infection. In particular, compounds and compositions may be for use in the treatment or prophylaxis of viral influenza.

Abstract: Squamous cell carcinomas, such as squamous head and neck cancer, are treated with a combination of radio-therapy and a therapeutic agent that reduces the amount of hsp27 in the squamous cancer cells. In specific embodiments, the therapeutic agent that reduces the amount of hsp27 is an antisense oligonucleotide therapeutic agent.

Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R5, X1, X2, X3 and X4 are as defined herein, and wherein the compound comprises at least one F, Cl, Br, I or 123I moiety, are provided. Uses of such compounds for imaging diagnostics in cancer and therapeutics methods for treatment of subjects in need thereof, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.

Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R1, R2, R3, R4, M1, M2, X, L1, L2, J1, J2, a1, a2, b1 and b2 are as defined herein, and wherein at least one of M2 or L2 is a moiety comprising an aziridine, acrylamide or sulfonate functional group, are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.

Abstract: Methods and devices for manufacturing polymer particles containing a therapeutic material and polymer conjugate particles comprising (a) introducing a first stream comprising a first solvent into a channel, wherein the channel has a first region adapted for flowing one or more streams introduced into the channel and a second region for mixing the contents of the one or more streams; (b) introducing a second stream comprising polymer conjugate in a second solvent into the channel to provide first and second streams flowing in the channel; (c) flowing the one or more first streams and the one or more second streams from the first region of the channel into the second region of the channel; (d) mixing of the contents of the one or more first streams and the one or more second streams flowing in the second region of the channel to provide a third stream comprising polymer conjugate nanoparticles.

Abstract: This invention provides the use of a polymer comprising a hyperbranched polyether polyol such as hyperbranched polyglycerol as a serum albumin substitute. Also provided are high molecular weight hyperbranched polyglycerol polymers suitable for a variety of medical and non-medical uses including methods for making such high molecular weight polymers.

Abstract: The invention includes methods and apparatus for separating heteroduplexed nucleic acids from homoduplexed nucleic acids having similar sequences and being at a much higher concentration. The heteroduplexed nucleic acids may be separated through the application of a time varying driving field and a time-varying mobility field to a sample of heteroduplexed and homoduplexed nucleic acids in a separation medium. Once the heteroduplexed nucleic acids are isolated and recovered, it is straightforward to analyze the sequences of the heteroduplexed nucleic acids, e.g., using sequencing or hybrid assays.

Abstract: In an example of a method for recovering lead from a lead material including lead sulfide, methane sulfonic acid is selected as a leaching acid for the lead material. The lead material is exposed to a solution including the methane sulfonic acid and i) ferric methane sulfonate or ii) oxygen, which leaches lead from the lead sulfide in the lead material, and generates a liquid leachate including a lead-methane sulfonate salt. The liquid leachate is purified, and lead is recovered from the purified liquid leachate using electrolysis.

Abstract: In an example of a method for recovering lead from a mixed oxidized lead material, methane sulfonic acid is selected as a leaching acid for the mixed oxidized lead material. The mixed oxidized lead material is exposed to a solution including the methane sulfonic acid, which leaches lead from any of a lead oxide or a lead carbonate in the mixed oxidized lead material, and generates a liquid leachate including a lead-methane sulfonate salt. The liquid leachate is purified, and lead is recovered from the purified liquid leachate using electrolysis.

Abstract: Methods and kits for detecting cancer and monitoring cancer progression are described. The method involves analyzing a sample containing nucleic acids or proteins from a patient for decreased expression of endoglycan and/or increased expression of podocalyxin.

Abstract: Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, J1, J2, X, Z, n1 and n2 are as defined herein, and wherein at least one of R1, R2 or R3 is an alkyl, alkenyl, aryl or aralkyl ester, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.